Malini Saba partakes in a brand new article discussing her journey and success. RENO, NV / ACCESS Newswire / May 13, 2025 / Dr. Malini Saba, a globally respected entrepreneur, psychologist, and ...

The innovative GeneSwift reagent kit from Gator Bio, along with GFP, CMV, and SV40 reagents, are designed to maintain the ...

Urges Shareholders to Vote FOR NHI's Director Nominees on the WHITE Proxy CardStrongly Disagrees with ISS' Recommendation; Believes that it Would Put at Risk Company's Superior Shareholder Returns ...

Receives U.S. Patent for Groundbreaking Treatment for Opioid Use DisorderClinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and ...

Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), ...

Surgeon-Turned-Philanthropist Calls for Action in Supporting Underserved Communities Worldwide ORANGE COUNTY, CA / ACCESS Newswire / May 13, 2025 / In a recent feature interview titled "Dr. Harrell E.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Beauty-Stem Biomedical, a biotech-driven beauty and wellness ...

LINCOLN, NEBRASKA / ACCESS Newswire / May 13, 2025 / Neighborhood LTC Pharmacy, a leader in pharmacy services for individuals with Intellectual and Developmental Disabilities (IDD), is thrilled to ...

New Investment Accelerates CERTIFY Health's Mission to Revolutionize Patient Engagement and Streamline Healthcare Operations GAITHERSBURG, MD / ACCESS Newswire / May 13, 2025 / CERTIFY Health, a ...

HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...

Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme ...